{"id":"asceniv","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion site reactions"},{"rate":null,"effect":"Thromboembolism"}]},"_chembl":null,"_dailymed":{"setId":"d74f4360-3b51-496c-96fb-84c3976958d2","title":"ASCENIV (HUMAN IMMUNOGLOBULIN G) LIQUID [ADMA BIOLOGICS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Asceniv is a human immune globulin intravenous (human) product derived from pooled human plasma. It contains a broad spectrum of antibodies that help replace deficient or dysfunctional immunoglobulins in patients with primary immunodeficiency disorders, thereby restoring immune competence and reducing infection risk.","oneSentence":"Asceniv is an intravenous immunoglobulin (IVIG) replacement therapy that provides polyclonal antibodies to boost immune function in patients with primary immunodeficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:18:45.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency (PI) disorders"}]},"trialDetails":[{"nctId":"NCT05070455","phase":"PHASE4","title":"An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)","status":"UNKNOWN","sponsor":"ADMA Biologics, Inc.","startDate":"2022-09-01","conditions":"Primary Immune Deficiency","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Asceniv™","genericName":"Asceniv™","companyName":"ADMA Biologics, Inc.","companyId":"adma-biologics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Asceniv is an intravenous immunoglobulin (IVIG) replacement therapy that provides polyclonal antibodies to boost immune function in patients with primary immunodeficiency. Used for Primary immunodeficiency (PI) disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}